BioSante Pharmaceuticals, Inc. has a strong portfolio of specialty products/candidates in the areas of sexual health and oncology. Employing a shrewd, collaborative framework of strategic partners/licensees, BioSante’s experienced development team has grown extremely proficient at identifying valuable opportunities and then leveraging the extended resources of the company’s partner network in order to progress rapidly from candidate towards a successfully branded product.
Lead products like LibiGel® (Phase III), a once-a-day transdermal gel engineered to absorb quickly into the skin after it is rubbed on the upper arm, show tremendous potential in targeted markets. In this case where women suffering from HSDD (hypoactive sexual desire disorder, characterized by lowered sex drive) benefit both from reduced skin reaction customary in other transdermal delivery solutions and the ability of the proprietary formulation of testosterone to alleviate HSDD symptoms, increasing sexual desire and satisfaction, while lowering sexual distress.
BioSante’s Elestrin™ gel, marketed in the US by BPAX licensee Azur Pharma, is an ultra-low dose prescription formulation of estrogen (estradiol) for hot flashes associated with menopause and engineered along emerging guidelines for such treatments from estrogen therapy/gynecology experts at the FDA, NAMS (North American Menopause Society) and ACOG (American College of Obstetricians and Gynecologists), who recommend the lowest dosage possible for the shortest interval. Fast-drying and colorless, this clear gel product contains a form of estradiol identical to that in the body; a single dose rubbed into the upper arm or shoulder is enough to treat moderate-to-severe hot flashes.
Rounding out the BioSante portfolio are three other offerings. The Pill-Plus™, an oral contraceptive that is currently under development, featuring a triple component formulation which adds an androgen (similar to testosterone) to the typical estrogen/progestin combination and has shown results in trials of increased sexual activity. Bio-T-Gel™, a once-daily transdermal formulation of testosterone engineered to treat male hypogonadism, typically characterized by impotence, osteoporosis, and weakness of the muscles, in addition to a general lack of sex drive. And finally, a series of ongoing cancer vaccine work with multiple offerings in various Phase I and II clinical trials, work that has been supercharged by the 2010 FDA approval of Provenge for the treatment of prostate cancer.
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
